China FDA Clarifies Legal Consequences of Clinical Trial Data Inspections

Published date31 August 2016
Law FirmRopes & Gray LLP
AuthorKatherine Wang,Mark Barnes
Subject MatterLife Sciences,China,Clinical Trials,Regulatory Reform,China FDA,Pharmaceutical Industry

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT